Immunem checkpoints are control pathways which preserve immune balance but can be hijacked by cancer cells to escape from immune monitoring. The session "Immune Checkpoints" is dedicated to the understanding of the mechanisms and their therapeutic targeting to improve anti-cancer immunity.".
These key checkpoints, including PD-1, PD-L1, and CTLA-4, are brakes on T-cell function. Cancers can overexpress these molecules to dampen immune responses, promoting uncontrolled growth and metastasis. Immune checkpoint inhibitors work by blocking these pathways to re-engage T cells to effectively recognize and attack cancer cells.
The session discusses clinical uses of checkpoint inhibitors in several cancer types such as melanoma, lung cancer, and hematologic malignancies. It discusses combination strategies using chemotherapy, targeted therapy, or other immunotherapies to overcome resistance and enhance response rates. Biomarker-based patient selection and monitoring are essential for maximizing efficacy and avoiding immune-related side effects.
Participants will be enlightened with the biology, therapeutic utility, and ongoing research on immune checkpoints. This session highlights the game-changing potential of checkpoint-targeted therapies in cancer treatment, offering long-lasting responses, enhancing survival, and opening the door to personalized, immune-based cancer therapies
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
